FDA approves daraxonrasib for pancreatic cancer — doubles survival vs chemotherapy

The FDA has approved daraxonrasib, a new drug for pancreatic cancer. In a large-scale clinical trial, patients taking the drug lived twice as long on average as those receiving standard chemotherapy. The approval marks a significant breakthrough in treating one of the most difficult-to-cure cancers.